StonvexLoading…
StonvexStonvexStonvexCore line items from AVNT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $3.26B | $3.24B | $3.14B | $3.40B |
Operating Income | $203.50M | $329.30M | $196.80M | $243.30M |
Net Income | $81.90M | $169.50M | $75.70M | $703.10M |
EPS (Diluted) | $0.89 | $1.84 | $0.83 | $7.63 |
Total Assets | $6.03B | $5.81B | $5.97B | $6.08B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $510.50M | $544.50M | $545.80M | $641.10M |
Free Cash Flow OCF − CapEx | $195.00M | $134.90M | $82.20M | $292.90M |
Shares Outstanding | 91.80M | 92.00M | 91.80M | 92.20M |